Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 8 September 2009, doi:10.1136/bmj.b3305
Cite this as: BMJ 2009;339:b3305
Sofie Decock, hepatologist1, Phyllis McGee, nurse practitioner with interest in autoimmune liver disease2, Gideon M Hirschfield, assistant professor of medicine2
1 AZ Sint-Lucas, Belgium , 2 The Liver Centre, Toronto Western Hospital, Toronto, ON, Canada, M5T 2S8
Correspondence to: Dr Gideon M Hirschfield, Toronto Western Hospital, 399 Bathurst Street, 6B Fell Pavilion, Toronto, ON, M5T 2S8 gideon.hirschfield@uhn.on.ca
| The first 150 words of the full text of this article appear below. |
|
Autoimmune hepatitis, primary biliary cirrhosis, and sclerosing cholangitis represent perhaps 5% of all liver diseases, although no registries exist to estimate the true prevalence. They are presumed autoimmune conditions, usually considered as a diagnosis after viral, metabolic, and drug induced liver injuries have been excluded. The combination of medical and surgical treatments means that, if appropriately diagnosed and managed, these diseases overall have an excellent prognosis. We review these
Biology
Clinical
Symptoms
For healthcare professionals
For patients
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses